Literature DB >> 34014144

Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI.

Yufan Zheng1, Jessica Dudman2, Jacqueline T Chen2, Kedar R Mahajan3, Danielle Herman2, Robert J Fox4, Daniel Ontaneda4, Bruce D Trapp2, Kunio Nakamura1.   

Abstract

BACKGROUND: Detecting cortical demyelination using magnetic resonance imaging (MRI) in multiple sclerosis (MS) remains a challenge. Magnetization transfer ratio (MTR), T1-weighted/T2-weighted ratio (T1T2R), and T2-weighted (T2w) signal are sensitive to cortical demyelination, but their accuracy is unknown.
OBJECTIVES: To quantify the sensitivity, specificity, and accuracy of postmortem T1T2R, MTR, and T2w in detecting cortical demyelination.
METHODS: In situ postmortem MRIs from 9 patients were used to measure T1T2R, MTR, and T2w along the midline of cortical gray matter and classified as normal or abnormal. MRIs were co-registered and compared to hemispheric myelin staining. The sensitivity, specificity, and accuracy of T1T2R, MTR, and T2w in detecting cortical demyelination were measured.
RESULTS: The mean age (standard deviation) at death was 64.7 (+/-13.7) years with a disease duration of 23.8 (+/-10.5) years. The sensitivity was 78% for MTR, 75% for T1T2R, and 63% for T2w. The specificity was 46% (T2w), 13% (T1T2R), and 29% (MTR). The accuracy was 71% (T2w), 39% (MTR), and 42% (T1T2R). There were no significant differences between different MRI measures in cortical demyelination or intracortical/subpial lesion detection.
CONCLUSIONS: Although somewhat sensitive, the modest specificity of conventional MRI modalities for cortical demyelination indicates that they are influenced by cortical changes other than demyelination. Improved acquisition and post-processing are needed to reliably measure cortical lesion load.

Entities:  

Keywords:  Cortical demyelination; MRI; PLP; T1-to-T2 ratio; histology-MRI correlation; magnetization transfer ratio; multiple sclerosis

Mesh:

Year:  2021        PMID: 34014144      PMCID: PMC8605037          DOI: 10.1177/13524585211014760

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  30 in total

1.  In vivo quantitative magnetization transfer imaging correlates with histology during de- and remyelination in cuprizone-treated mice.

Authors:  Laura Turati; Marco Moscatelli; Alfonso Mastropietro; Nicholas G Dowell; Ileana Zucca; Alessandra Erbetta; Chiara Cordiglieri; Greta Brenna; Beatrice Bianchi; Renato Mantegazza; Mara Cercignani; Fulvio Baggi; Ludovico Minati
Journal:  NMR Biomed       Date:  2015-01-09       Impact factor: 4.044

2.  Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging.

Authors:  David Pitt; Aaron Boster; Wei Pei; Eric Wohleb; Adam Jasne; Cherian R Zachariah; Kottil Rammohan; Michael V Knopp; Petra Schmalbrock
Journal:  Arch Neurol       Date:  2010-07

3.  Postmortem verification of MS cortical lesion detection with 3D DIR.

Authors:  A Seewann; E-J Kooi; S D Roosendaal; P J W Pouwels; M P Wattjes; P van der Valk; F Barkhof; C H Polman; J J G Geurts
Journal:  Neurology       Date:  2012-01-04       Impact factor: 9.910

4.  Focal cortical lesion detection in multiple sclerosis: 3 Tesla DIR versus 7 Tesla FLASH-T2.

Authors:  A Scott Nielsen; R Philip Kinkel; Emanuele Tinelli; Thomas Benner; Julien Cohen-Adad; Caterina Mainero
Journal:  J Magn Reson Imaging       Date:  2011-11-01       Impact factor: 4.813

5.  Increased cortical grey matter lesion detection in multiple sclerosis with 7 T MRI: a post-mortem verification study.

Authors:  Iris D Kilsdonk; Laura E Jonkman; Roel Klaver; Susanne J van Veluw; Jaco J M Zwanenburg; Joost P A Kuijer; Petra J W Pouwels; Jos W R Twisk; Mike P Wattjes; Peter R Luijten; Frederik Barkhof; Jeroen J G Geurts
Journal:  Brain       Date:  2016-03-08       Impact factor: 13.501

6.  Ultra-High-Field MRI Visualization of Cortical Multiple Sclerosis Lesions with T2 and T2*: A Postmortem MRI and Histopathology Study.

Authors:  L E Jonkman; R Klaver; L Fleysher; M Inglese; J J G Geurts
Journal:  AJNR Am J Neuroradiol       Date:  2015-07-30       Impact factor: 3.825

7.  Comprehensive Autopsy Program for Individuals with Multiple Sclerosis.

Authors:  Ranjan Dutta; Kedar R Mahajan; Kunio Nakamura; Daniel Ontaneda; Jacqueline Chen; Christina Volsko; Jessica Dudman; Emilie Christie; Jordon Dunham; Robert J Fox; Bruce D Trapp
Journal:  J Vis Exp       Date:  2019-07-19       Impact factor: 1.355

8.  Gray matter SWI-filtered phase and atrophy are linked to disability in MS.

Authors:  Jesper Hagemeier; Bianca Weinstock-Guttman; Mari Heininen-Brown; Guy U Poloni; Niels Bergsland; Claudiu Schirda; Christopher R Magnano; Cheryl Kennedy; Ellen Carl; Michael G Dwyer; Alireza Minagar; Robert Zivadinov
Journal:  Front Biosci (Elite Ed)       Date:  2013-01-01

9.  Cortical pathology in multiple sclerosis detected by the T1/T2-weighted ratio from routine magnetic resonance imaging.

Authors:  Ruthger Righart; Viola Biberacher; Laura E Jonkman; Roel Klaver; Paul Schmidt; Dorothea Buck; Achim Berthele; Jan S Kirschke; Claus Zimmer; Bernhard Hemmer; Jeroen J G Geurts; Mark Mühlau
Journal:  Ann Neurol       Date:  2017-09-16       Impact factor: 10.422

10.  Whole brain myelin mapping using T1- and T2-weighted MR imaging data.

Authors:  Marco Ganzetti; Nicole Wenderoth; Dante Mantini
Journal:  Front Hum Neurosci       Date:  2014-09-02       Impact factor: 3.169

View more
  2 in total

1.  Gd2O3-mesoporous silica/gold nanoshells: A potential dual T1/T2 contrast agent for MRI-guided localized near-IR photothermal therapy.

Authors:  Yara Kadria-Vili; Oara Neumann; Yage Zhao; Peter Nordlander; Gary V Martinez; James A Bankson; Naomi J Halas
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-11       Impact factor: 12.779

2.  T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No.

Authors:  Mark Mühlau
Journal:  Mult Scler       Date:  2022-01-22       Impact factor: 6.312

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.